Status:
TERMINATED
Anticholinergic Burden in Schizophrenia
Lead Sponsor:
Centre for Addiction and Mental Health
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
Anticholinergic antiparkinsonian agents often cause side-effects including cognitive impairment, dry mouth, and constipation while they diminish antipsychotic-induced parkinsonian symptoms. The introd...
Detailed Description
Anticholinergic antiparkinsonian agents (AAAs) are frequently prescribed in patients with a primary psychotic disorder either to treat or prevent the emergence of antipsychotic induced extrapyramidal ...
Eligibility Criteria
Inclusion
- Age of 50 and older
- DSM-IV/SCID diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or psychotic disorder NOS
- Having been treated with benztopine at a steady daily dose of 3 mg or less for at least three months
- Having been treated with risperidone, quetiapine, olanzapine, or clozapine at a steady dose for at least two weeks.
- Willingness to provide consent for investigator to communicate with their physician of record regarding their participation in the study.
Exclusion
- Unstable physical illness or clinically significant neurological disorder
- A history of severe or life-threatening dystonia
- Presence of EPS defined as a total score of 7 or more or a score of 3 or more on any individual item on the SAS at baseline
- Positive urine drug screen for illegal drugs
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00715377
Start Date
June 1 2007
End Date
December 1 2011
Last Update
August 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M5T 1R8